tc-zher2:4107
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2025 (NCT07292571)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Radiopharmaceutical
ERBB2 radiopharmaceutical
Chemistry & pharmacology
- Payload
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07292571 | Phase 2 | Oct 20, 2025 | Russian Academy of Medical Sciences, Uppsala University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Russian Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1